In the NSG xenograft model, CD19/20/22 CAR-T cells showed more potent inhibition of CD19(−) leukemia cells in patients who failed CD19 CAR-T cell therapy, which was challenging to inhibit CD19 CAR-T cells [90]. Here, CD19 is linked to leukemia.